Hyoscyamine sulfate 0.125 MG Oral Tablet [Digenyx] — RxCUI 2743192
RxNorm drug concept · Semantic branded drug
RxCUI 2743192
Semantic branded drug · SBD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2743192
Official nameHyoscyamine sulfate 0.125 MG Oral Tablet [Digenyx]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asDigenyx 0.125 MG Oral Tablet
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Hyoscyamine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Hyoscyamine calms spasms and slows secretions in the stomach, bowel and bladder. It is often an add-on for peptic ulcer or irritable bowel syndrome. Some products have additional u...
- Many tablets are taken 30 to 60 minutes before meals and at bedtime, and some are taken as needed. Follow your label, since dissolving, under-the-tongue and extended-release forms...
- Dry mouth, blurred vision, drowsiness, dizziness and constipation are common. Use caution driving until you know how it affects you. Call your doctor if you cannot urinate or feel...
- Be careful. Hyoscyamine reduces sweating, so you can overheat and even get heat stroke. Stay cool and get help for fever or heat illness.
🕸️ Concept Web — How Hyoscyamine sulfate 0.125 MG Oral Tablet [Digeny... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Hyoscyamine sulfate 0.125 MG Oral Tablet [Digenyx]
RxCUI 2743192 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Hyoscyamine
153970IN -
Hyoscyamine sulfate
1225PIN
-
Hyoscyamine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Digenyx
2743186BN
-
Digenyx
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Hyoscyamine Oral Tablet
370666SCDF -
Hyoscyamine sulfate Oral Tablet
2646727SCDFP -
Hyoscyamine Oral Product
1165278SCDG -
Hyoscyamine Pill
1165279SCDG -
Hyoscyamine sulfate Oral Product
2659505SCDGP -
Hyoscyamine sulfate Pill
2661552SCDGP -
Hyoscyamine Oral Tablet [Digenyx]
2743190SBDF -
Hyoscyamine sulfate Oral Tablet [Digenyx]
2743191SBDFP - +5 more in this family
-
Hyoscyamine Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Hyoscyamine sulfate 0.125 MG Oral Tablet
1047905SCD -
Hyoscyamine sulfate 0.125 MG
1046981SCDC -
Hyoscyamine sulfate 0.125 MG [Digenyx]
2743187SBDC
-
Hyoscyamine sulfate 0.125 MG Oral Tablet
Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Hyoscyamine sulfate 0.125 MG Oral Tablet
SCD · 1047905 -
Hyoscyamine sulfate 0.125 MG
SCDC · 1046981 -
Hyoscyamine Oral Tablet
SCDF · 370666 -
Hyoscyamine sulfate Oral Tablet
SCDFP · 2646727 -
Hyoscyamine Oral Product
SCDG · 1165278 -
Hyoscyamine Pill
SCDG · 1165279 -
Hyoscyamine sulfate Oral Product
SCDGP · 2659505 -
Hyoscyamine sulfate Pill
SCDGP · 2661552
Brand-Name Concepts
-
Hyoscyamine sulfate 0.125 MG [Digenyx]
SBDC · 2743187 -
Hyoscyamine Oral Tablet [Digenyx]
SBDF · 2743190 -
Hyoscyamine sulfate Oral Tablet [Digenyx]
SBDFP · 2743191 -
Digenyx Oral Product
SBDG · 2743188 -
Digenyx Pill
SBDG · 2743189 -
Digenyx
BN · 2743186
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 2743192 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 59088-0150-54 | 30 TABLET in 1 BOTTLE (59088-150-54) | Digenyx | PureTek Corporation | 2026-05-13 |
Observed labelers:
PureTek Corporation (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.